Finance

Biotech By Matthew Herper

Bristol Myers Squibb to buy MyoKardia for $13 billion

Health Tech By Rebecca Robbins and Erin Brodwin

What we learned about the digital pharmacy business from Hims & Hers filing to go public

Pharmalot By Ed Silverman

Not by the numbers: Former Aceto controller is charged with insider trading

Pharmalot By Ed Silverman

Novartis sells bonds tied to expanding access to medicines in poor countries

Something Ventured By Kate Sheridan

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Health Tech By Andy Rosen — Boston Globe

Biofourmis raises $100 million for remote patient monitoring tools

Health Tech By Rebecca Robbins

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Health Tech By Rebecca Robbins

Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming opposition from Novartis

Health Tech By Rebecca Robbins

Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech

Telemedicine - phone and stethoscope telehealth

Health Tech By Erin Brodwin

Teladoc rival MDLive is preparing to go public next year

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

Health Tech By Rebecca Robbins, Casey Ross, and Erin Brodwin

10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo

Health Tech By Rebecca Robbins

Earnings season highlights how health tech companies fared in the first full quarter of the pandemic

Health By Rebecca Robbins

Medical nonprofits are hard-hit as the pandemic upends crucial fundraising

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers

Pharma By Kate Sheridan

Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets

Health Tech By Rebecca Robbins

MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist

Biotech By STAT staff

STAT+ Conversations: Which biotech venture capitalist funds are performing best?

Biotech By Kate Sheridan

Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns

First Opinion By Eric Letsinger and Alison Rein

Invest in community-based organizations to put health dollars where they are really needed

Health Tech By Erin Brodwin

Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads

Health Tech By Erin Brodwin

As European Commission decision looms, Google faces continued scrutiny over Fitbit deal

Health Tech By Juliet Isselbacher

Proving predictions wrong, health tech funding keeps climbing

Health Tech By Rebecca Robbins

Most Read

When private equity firms invest in women’s health clinics, who benefits?

How much is a startup worth? For biotech companies, the answer is rarely public

The novel coronavirus is a serious threat. We need to prepare, not overreact

Blackstone agrees to buy Ancestry in $4.7 billion deal

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

Teladoc Health reaches agreement to buy Livongo in a $18.5 billion deal

The Indian pharmaceutical industry is in denial over drug-quality charges

How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition

All Coverage

Bristol Myers Squibb to buy MyoKardia for $13 billion

What we learned about the digital pharmacy business from Hims & Hers filing to go public

Not by the numbers: Former Aceto controller is charged with insider trading

Novartis sells bonds tied to expanding access to medicines in poor countries

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Biofourmis raises $100 million for remote patient monitoring tools

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming opposition from Novartis

Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech

Teladoc rival MDLive is preparing to go public next year

4 questions for neurology startups as venture investors pour millions into the field

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo

Earnings season highlights how health tech companies fared in the first full quarter of the pandemic

Medical nonprofits are hard-hit as the pandemic upends crucial fundraising

Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers

Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets

MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist

STAT+ Conversations: Which biotech venture capitalist funds are performing best?

Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns

Invest in community-based organizations to put health dollars where they are really needed

Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads

As European Commission decision looms, Google faces continued scrutiny over Fitbit deal

Proving predictions wrong, health tech funding keeps climbing

Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka

Most Read

All Coverage